Premium
Germinal center B (GCB) and non‐GCB cell‐like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation
Author(s) -
Costa Luciano J.,
Feldman Andrew L.,
Micallef Iva.,
Inwards David J.,
Johnston Patrick B.,
Porrata Luis F.,
Ansell Stephen M.
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07207.x
Subject(s) - carmustine , medicine , melphalan , etoposide , transplantation , diffuse large b cell lymphoma , oncology , hematopoietic stem cell transplantation , salvage therapy , stem cell , progression free survival , cytarabine , lymphoma , surgery , chemotherapy , biology , genetics
Summary Patients with germinal center B cell‐like (GCB) and non‐GCB diffuse large B cell lymphomas (DLBCL) receiving first line therapy have distinct prognosis. We explored the differences in outcome following salvage autologous hematopoietic stem cell (HSC) transplantation between patients with GCB and non‐GCB DLBCL. Forty‐four patients with relapsed and 15 patients with primary refractory chemosensitive disease undergoing BEAM (BCNU [carmustine], etoposide, cytarabine, melphalan) conditioning and autologous HSC were included. Immunohistochemical analysis was performed for CD10, BCL‐6, MUM1 (allowing classification into GCB and non‐GCB‐like DLBCL) and BCL‐2. Median follow‐up of survivors was 25 months; median age at the time of transplantation was 60 years (range 17–77). Thirty‐two patients (54%) were classified as having GCB and 27 (46%) as having non‐GCB‐like DLBCL. Patients with GCB and non‐GCB DLBCL did not differ in the risk of progression after HSC transplant ( P = 0·78) or overall survival ( P = 0·48). In multivariate analysis, only time to progression after initial treatment impacted overall survival. We conclude that patients with relapsed or primary refractory chemosensitive GCB and non‐GCB‐like DLBCL derive similar benefit from autologous HSC transplant.